Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, in Subjects With Refractory Generalized Myasthenia Gravis (KYSA-6)

Next Previous
Trial Profile

A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, in Subjects With Refractory Generalized Myasthenia Gravis (KYSA-6)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mivocabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KYSA-6
  • Sponsors Kyverna Therapeutics

Most Recent Events

  • 12 Nov 2025 According to a Kyverna therapeutics media release, Interim results from the trial were presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in October 2025.
  • 29 Oct 2025 According to a Kyverna therapeutics media release, company look forward to initiating enrollment for the Phase 3 portion of the trial by the end of this year, as well as sharing updated data from the Phase 2 portion of the trial next year.
  • 29 Oct 2025 Interim results published in the Kyverna Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top